Colorectal cancer mortality is increasingly a problem for adults under 65 — a demographic once considered relatively protected — making the timing of this guideline update particularly consequential. The expanded toolkit for early detection now includes technologies that did not exist when the previous framework was set, potentially reshaping how millions of average-risk adults engage with screening.
The American Cancer Society's 2026 update reaffirms the 2018 lowering of the recommended screening initiation age to 45 for average-risk adults, extending through age 75 for those with greater than 10 years of life expectancy. Critically, the update formally integrates three newly approved molecular-based tests into its recommended options: a next-generation multitarget stool DNA (mt-sDNA) assay, a multitarget stool RNA (mt-sRNA) test, and a blood-based cell-free DNA (cfDNA) assay. The evidence review, commissioned through a targeted systematic analysis and modeling studies, found that both the next-generation mt-sDNA and mt-sRNA tests demonstrated high sensitivity for detecting established colorectal cancer and moderate sensitivity for advanced precancerous lesions. The blood-based cfDNA test received conditional inclusion, underscoring that liquid biopsy screening remains early-stage relative to established stool-based approaches.
From a broader research perspective, this update reflects a meaningful shift: screening is evolving from a binary choice between colonoscopy and basic stool tests toward a graduated menu of molecular options with meaningfully different sensitivity and specificity profiles. The addition of blood-based testing is particularly notable — patient compliance with invasive or stool-based procedures has long been a structural barrier, and even a test with lower sensitivity may outperform a theoretically superior test that goes uncompleted. The ACS explicitly acknowledges this, reiterating that the most effective test is the one a patient actually completes. A key limitation is that long-term mortality outcome data for the newer assays remain limited; current recommendations rest substantially on modeling rather than decades of randomized trial evidence available for colonoscopy. This update is best characterized as confirmatory of the 45-year age threshold and incrementally expansive on test options — not a paradigm shift, but a clinically meaningful broadening of an evidence-based framework.